Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|July 14, 2015

Clinical Research Sites Invited to Nominate Innovative Enrollment Plans for SCRS' SPRIA

Ellicott City, M.D., July 14, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests and voice of clinical research sites, today announced that it is accepting submissions for its annual Site Patient Recruitment Innovation Award (SPRIA), which recognizes sites that employ innovative strategies to achieve enrollment success. The winner will be recognized at SCRS’ Global Site Solutions Summit, which takes place October 8-11, at Amelia Island, FL.

In judging submissions, emphasis is placed on innovative patient-directed initiatives that are unique, effective and take into account the response of the campaign. All sites are invited to submit their recruitment plans for the SPRIA, which was launched in 2014 to great success.

An independent judging panel will select three finalists from the submissions. The finalists will be invited to attend the Site Solutions Summit with a complimentary registration. At the summit, the finalists will present their plans to an audience of executives from sites, sponsors, and CROs. The judging panel then will determine the winner. Sites deserving Honorary Mention for innovation in patient recruitment will be honored with a poster presentation in the SCRS SPRIA Gallery at the Summit. The SPRIA is sponsored by Acurian.

Nominations forms can be downloaded on the Global Site Solutions Summit website. Completed form should be sent to SPRIA@myscrs.org by July 31, 2015.

DM Clinical Research won last year’s inaugural SPRIA .

 


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.